There appears to be an 80% decreased chance of hospital admission if Rx'd Hydroxycholoquine in combination with Azithromycin and Zinc as soon as a person is found to test positive or show symptoms. According to the supposedly accurate data on COVID cases/ admissions to hospital, and deaths, this would equate to about 70,000 lives that could have been saved that weren't because the liberal media and the liberal AMA et al could not allow it's use because President Trump advocated it, and it offered hope at a time when they needed to bring Trump down.
All of the reasons cited by the AMA in its' reversal in it's November 2020 meeting minutes released this week (which was buried deep within their minutes) was available last Spring and certainly by the beginning of July when the Henry Ford study came out. I mentioned all of these points and even cited the weakness of the data and studies being held up as a reason to not use Hydroxychloroquine that they now cite as unreliable (including the rescinded articles from the NEJM). NONE OF THE REASONS GIVEN REPRESENTS NEW INFORMATION NOT ALREADY KNOWN SINCE LAST SUMMER.
But while I only have 30+ yrs as an MD, a long clinical practice history, National Specialty Board Certification, and have done actual research, this could not compare to the education of HydroxychloroJim, Conor, and the other libs on this board who went through the heated crucible of an hour long CNN special with Jake Tapper.
I would laugh at you right now if it wasn't so sad for our country. Removing Trump "by any means necessary" was your credo - and you and fellow academic liberals in the AMA were willing to hurt patients to accomplish your goal of hiding the fact that Trump was right yet again.
Here is the copied and pasted pertinent part of the AMA minutes, and I have provided the link as well:
AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES
Resolution: 509
(November 2020)
Introduced by: Georgia
Subject: Hydroxychloroquine and Combination Therapies – Off-Label Use
Referred to: Reference Committee E
1 Whereas, SARS-CoV-2 is the novel coronavirus that causes COVID-19; and
2
3 Whereas, Three distinct stages of COVID-19 infection have been observed in some people who
4 test positive for the disease and have variable degrees of symptoms as noted (1); and
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31 Whereas, During the early infection phase (Stage 1), the virus multiplies inside the body and is
32 likely to cause mild symptoms that may be confused with a common cold or flu; and
33
34 Whereas, The second phase is the pulmonary phase (Stage 2), when the Immune
35 System becomes strongly affected by infection and leads to primarily respiratory symptoms
36 such as persistent cough, shortness of breath and low oxygen levels. Problems with blood
37 clotting--especially with the formation of blood clots--may be predominant in Stage 2; and
Resolution: 509 (November 2020)
Page 2 of 6
1 Whereas, The third hyperinflammatory phase (Stage 3), occurs when a hyperactivated immune
2 system may cause injury to the heart, kidneys, and other organs. A "cytokine storm"--where the
3 body attacks its own tissues--may occur in this phase; and
4
5 Whereas, There is no current Federal Drug Administration (FDA) indication for the treatment of
6 Early Coronavirus infection, but early emergency use authorization (EUA) originally approved
7 the use of hydroxychloroquine and then rescinded it (2); and
8
9 Whereas, The FDA limited use of convalescence plasma but now has rescinded that
10 limitation (3); and
11
12 Whereas, Hydroxychloroquine and Chloroquine are FDA approved medications for over
13 50 years, and these medications are safely prescribed long-term for other indications (2); and
14
15 Whereas, AMA President, Patrice A. Harris, MD, issued the following statement: “The AMA
16 is calling for a stop to any inappropriate prescribing and ordering of medications, including
17 chloroquine or hydroxychloroquine, and appealing to physicians and all health care
18 professionals to follow the highest standards of professionalism and ethics” (4); and
19
20 Whereas, The AMA, American Pharmacists Association, and American Society of Health
21 System Pharmacists issued a joint statement on March 25, 2020 on inappropriate ordering,
22 prescribing, or dispensing of medications to treat COVID-19 (4); and
23
24 Whereas, Some states, pharmacy boards and institutions have forbidden the use of these
25 medications for COVID-19 infection (4, 5); and
26
27 Whereas, A proposed regimen to treat COVID-19 for Stage 1, includes 10 days of
28 hydroxychloroquine, Azithromycin, zinc, and on occasion Vitamin D (6); and
29
30 Whereas, This regimen is not being advocated for Stage 2 and Stage 3 COVID therapy; and
31
32 Whereas, The original studies published in The Lancet and The New England Journal of
33 Medicine (NEJM) initially citing harm due to hydroxychloroquine and chloroquine use were
34 retracted by said journals due to dubious research methodology and incorrect conclusions
35 (7, 8, 9); and
36
37 Whereas, AMA policy H-120.988, “Patient Access to Treatments Prescribed by Their
38 Physicians,” supports a physician’s autonomy to prescribe medications the physician believes to
39 be in the patient’s best interest, where the benefits outweigh risk and the patient consents; and
40
41 Whereas, Physicians have used off label medications for years and this use is supported by
42 existing policy; and
43
44 Whereas, Data regarding harm have been limited due to poorly designed studies or studies
45 usually in Stage 2 or later, or stopped without harm but no effect in phase 2 and hypothesis
46 (7, 8, 9, 10, 11, 12); and
47
48 Whereas, There are many studies that indicate that the use of Hydroxychloroquine,
49 Azithromycin is effective and front-line physicians are using the therapy where permissible
50 (13, 14, 15); and
Resolution: 509 (November 2020)
Page 3 of 6
1 Whereas, The COVID-19 pandemic is a serious medical issue, people are dying, and
2 physicians must be able to perform as sagacious prescribers; therefore be it
3
4 RESOLVED, That our American Medical Association rescind its statement calling for physicians
5 to stop prescribing hydroxychloroquine and chloroquine until sufficient evidence becomes
6 available to conclusively illustrate that the harm associated with use outweighs benefit early in
7 the disease course. Implying that such treatment is inappropriate contradicts AMA Policy
8 H-120.988, “Patient Access to Treatments Prescribed by Their Physicians,” that addresses off
9 label prescriptions as appropriate in the judgement of the prescribing physician (Directive to
10 Take Action); and be it further
11
12 RESOLVED, That our AMA rescind its joint statement with the American Pharmacists
13 Association and American Society of Health System Pharmacists, and update it with a joint
14 statement notifying patients that further studies are ongoing to clarify any potential benefit of
15 hydroxychloroquine and combination therapies for the treatment of COVID-19 (Directive to Take
16 Action); and be it further
17
18 RESOLVED, That our AMA reassure the patients whose physicians are prescribing
19 hydroxychloroquine and combination therapies for their early-stage COVID-19 diagnosis by
20 issuing an updated statement clarifying our support for a physician’s ability to prescribe an FDA21 approved medication for off label use, if it is in her/his best clinical judgement, with specific
22 reference to the use of hydroxychloroquine and combination therapies for the treatment of the
23 earliest stage of COVID-19 (Directive to Take Action); and be it further
24
25 RESOLVED, That our AMA take the actions necessary to require local pharmacies to fill valid
26 prescriptions that are issued by physicians and consistent with AMA principles articulated in
27 AMA Policy H-120.988, “Patient Access to Treatments Prescribed by Their Physicians,”
28 including working with the American Pharmacists Association and American Society of Health
29 System Pharmacists. (Directive to Take Action)
Fiscal Note: Modest - between $1,000 - $5,000
Received: 10/23/20
References:
1. Stages of COVID-19. https://emergencymedicinecases.com/covid-19-screening-diagnosis-management/
2. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorizationchloroquine-and
3. Recommendations for Investigational COVID-19 Convalescent Plasma. https://www.fda.gov/vaccines-bloodbiologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-
convalescent-plasma
4. “The A.M.A. is calling for a stop to any inappropriate prescribing and ordering of medications, including chloroquine or
hydroxychloroquine, and appealing to physicians and all health care professionals to follow the highest standards of professionalism
and ethics,” said AMA President Patrice A. Harris, MD.
The American Medical Association, American Pharmacists Association, and American Society of Health System Pharmacists issued
a j oint statement on March 25, 2020 on inappropriate ordering, prescribing or dispensing of medications to treat COVID-19.
https://www.ama-assn.org/system/files/2020-04/board-of-pharmacy-covid-19-prescribing.pdf
5. Pharmacy Practice New. Rosenthal M. Hydroxychloroquine: Where Pharmacy, Medicine and Politics Intersect, Pharmacy
Practice News August 8, 2020
6. Risch H. Opinion: Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up
Immediately as Key to the Pandemic Crisis Am J Epidemiol. 2020 May 27;kwaa093. doi: 10.1093/aje/kwaa093. Online ahead of
print.
7. Piller C, Servick k. Two elite medical journals retract coronavirus papers over data integrity questions.
https://www.sciencemag.org/news/2020/06/two-elite-medical-journals-retract-coronavirus-papers-over-data-integrity-questions#
June 4, 2020
8. Lancet retraction website https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931180-6
9. NEJM Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621.
11. NIH halts clinical trial of hydroxychloroquine https://www.nih.gov/news-events/news-releases/nih-halts-clinical-trial-hydr
Link: https://www.ama-assn.org/system/files/2020-10/nov20-handbook-addendum.pdf